"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
| Descriptor ID |
D059016
|
| MeSH Number(s) |
G04.366.500
|
| Concept/Terms |
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Cancer Microenvironment- Cancer Microenvironment
- Cancer Microenvironments
- Microenvironment, Cancer
- Microenvironments, Cancer
|
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in this website by year, and whether "Tumor Microenvironment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2010 | 7 | 7 | 14 |
| 2011 | 16 | 24 | 40 |
| 2012 | 16 | 16 | 32 |
| 2013 | 14 | 20 | 34 |
| 2014 | 20 | 20 | 40 |
| 2015 | 20 | 31 | 51 |
| 2016 | 41 | 37 | 78 |
| 2017 | 21 | 51 | 72 |
| 2018 | 22 | 52 | 74 |
| 2019 | 35 | 68 | 103 |
| 2020 | 42 | 90 | 132 |
| 2021 | 35 | 111 | 146 |
| 2022 | 13 | 161 | 174 |
| 2023 | 5 | 150 | 155 |
| 2024 | 45 | 79 | 124 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas. Int J Mol Sci. 2024 Dec 07; 25(23).
-
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. Neuro Oncol. 2024 Dec 05; 26(12):2239-2255.
-
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy. Cells. 2024 Dec 03; 13(23).
-
Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment. Cancer Immunol Res. 2024 Dec 03; 12(12):1736-1752.
-
HSP90 inhibitor AUY922 suppresses tumor growth and modulates immune response through YAP1-TEAD pathway inhibition in gastric cancer. Cancer Lett. 2025 Feb 01; 610:217354.
-
H2S-Prdx4 axis mitigates Golgi stress to bolster tumor-reactive T cell immunotherapeutic response. Sci Adv. 2024 Nov 15; 10(46):eadp1152.
-
Evidence that CRISPR-Cas9 Y537S-mutant expressing breast cancer cells activate Yes-associated protein 1 to driving the conversion of normal fibroblasts into cancer-associated fibroblasts. Cell Commun Signal. 2024 Nov 14; 22(1):545.
-
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.
-
Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon a gene therapy in a murine bladder cancer model. Front Immunol. 2024; 15:1387229.
-
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol. 2024 Nov 04; 26(11):2044-2060.